相关实验视频

Updated: Jun 5, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

阿布丁通过抑制瘤编程细胞死亡-干1表达来克服瘤免疫耐受性

Ching-Han Liu¹, Jing-Ru Weng², Li-Hsien Wu^2,3

¹Division of Cardiology, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan.

International journal of medical sciences

|December 4, 2024

概括

阿布丁是一种来自熊的化合物,通过减少编程细胞死亡连接体1 (PD-L1) 的表达,显示出在癌症治疗中的潜力. 这种机制增强了免疫系统的功能.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
在瘤学瘤学.

背景情况:

阿布丁是从熊植物中提取的,具有免疫调节特性.
编程细胞死亡-连接1/编程细胞死亡-1 (PD-L1/PD-1) 途径在癌症免疫逃避中至关重要.
调节PD-L1表达是瘤免疫疗法的关键策略.

研究的目的:

调查阿布丁因影响PD-L1表达的分子机制.
探索arbutin作为癌症免疫治疗剂的潜力.

主要方法:

用arbutin治疗瘤细胞.
对瘤细胞PD-L1表达水平的分析.
调查AKT/mTOR信号通路的参与.

主要成果:

阿布丁治疗导致PD-L1在瘤细胞表面的表达减少.
发现阿布丁通过蛋白激酶B (AKT) /哺乳动物目标拉巴胺素 (mTOR) 途径降低PD-L1的调节.
这种下调增强了对瘤的免疫反应.

结论:

阿布丁通过AKT/mTOR通路有效降低PD-L1的表达.
阿布丁表明具有保护作用,并为癌症免疫疗法提供了新的见解.
阿布丁可能是一个有价值的治疗剂,单独使用或结合治疗.

关键词:

在阿尔布丁胺.编程细胞死亡蛋白质联结-1 瘤免疫耐受性免疫耐受性

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...